CN107400635A - Import rhodotorula glutinis recombinant bacterial strain of α MSH polypeptides and its preparation method and application - Google Patents
Import rhodotorula glutinis recombinant bacterial strain of α MSH polypeptides and its preparation method and application Download PDFInfo
- Publication number
- CN107400635A CN107400635A CN201710370603.4A CN201710370603A CN107400635A CN 107400635 A CN107400635 A CN 107400635A CN 201710370603 A CN201710370603 A CN 201710370603A CN 107400635 A CN107400635 A CN 107400635A
- Authority
- CN
- China
- Prior art keywords
- msh
- bacterial strain
- rhodotorula glutinis
- importing
- recombinant bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 97
- 241000223253 Rhodotorula glutinis Species 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 title abstract description 36
- 230000008676 import Effects 0.000 title description 10
- 101710200145 Acyl-CoA 6-desaturase Proteins 0.000 claims abstract description 49
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 claims abstract description 42
- 230000029087 digestion Effects 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 108010022240 delta-8 fatty acid desaturase Proteins 0.000 claims abstract description 6
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims description 125
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 241000894006 Bacteria Species 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 20
- 238000005119 centrifugation Methods 0.000 claims description 18
- 230000005611 electricity Effects 0.000 claims description 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 14
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 claims description 11
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 claims description 11
- 238000004520 electroporation Methods 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 9
- 241001290628 Cunninghamella echinulata Species 0.000 claims description 8
- 238000010276 construction Methods 0.000 claims description 6
- 239000012154 double-distilled water Substances 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 3
- 229940057059 monascus purpureus Drugs 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 abstract description 90
- 239000013612 plasmid Substances 0.000 abstract description 38
- 230000014509 gene expression Effects 0.000 abstract description 30
- 210000002966 serum Anatomy 0.000 abstract description 27
- 210000004185 liver Anatomy 0.000 abstract description 22
- 241000699670 Mus sp. Species 0.000 abstract description 12
- 238000004458 analytical method Methods 0.000 abstract description 11
- 238000003753 real-time PCR Methods 0.000 abstract description 7
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 238000003780 insertion Methods 0.000 abstract description 4
- 230000037431 insertion Effects 0.000 abstract description 4
- 238000004817 gas chromatography Methods 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 80
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 55
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 54
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 54
- 229960002733 gamolenic acid Drugs 0.000 description 54
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 102000004196 processed proteins & peptides Human genes 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 36
- 238000000034 method Methods 0.000 description 31
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 30
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 230000003834 intracellular effect Effects 0.000 description 27
- 239000006228 supernatant Substances 0.000 description 27
- 210000001072 colon Anatomy 0.000 description 25
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 24
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 20
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 19
- 239000002158 endotoxin Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 229920006008 lipopolysaccharide Polymers 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102000004961 Furin Human genes 0.000 description 15
- 108090001126 Furin Proteins 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 14
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 13
- 238000012545 processing Methods 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 235000021342 arachidonic acid Nutrition 0.000 description 12
- 229940114079 arachidonic acid Drugs 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 11
- 102000003814 Interleukin-10 Human genes 0.000 description 10
- 108090000174 Interleukin-10 Proteins 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 102000003777 Interleukin-1 beta Human genes 0.000 description 9
- 108090000193 Interleukin-1 beta Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000008157 ELISA kit Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 108010087894 Fatty acid desaturases Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 6
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 210000002777 columnar cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000003097 mucus Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 102000009114 Fatty acid desaturases Human genes 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000005747 Transcription Factor RelA Human genes 0.000 description 4
- 108010031154 Transcription Factor RelA Proteins 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 238000006356 dehydrogenation reaction Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000002798 spectrophotometry method Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102100020754 Putative fatty acid desaturase 2-like protein FADS2B Human genes 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000004042 decolorization Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000004519 grease Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- -1 IL- 6th Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920012196 Polyoxymethylene Copolymer Polymers 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 241000223252 Rhodotorula Species 0.000 description 2
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 241001149952 Amylomyces rouxii Species 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100493713 Caenorhabditis elegans bath-45 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000606069 Chlamydiaceae Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000345386 Fabia Species 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 108010011713 delta-15 desaturase Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- WCYAALZQFZMMOM-UHFFFAOYSA-N methanol;sulfuric acid Chemical compound OC.OS(O)(=O)=O WCYAALZQFZMMOM-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 101150079312 pgk1 gene Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a kind of rhodotorula glutinis recombinant bacterial strain of importing α MSH polypeptides, and α MSH polypeptides are imported in the rhodotorula glutinis through the restructuring of the delta 8 desaturase genes of Δ 6.Invention additionally discloses a kind of preparation method and application of the rhodotorula glutinis recombinant bacterial strain of importing α MSH polypeptides.The present invention has the advantages that:Identified through double digestion, the purpose fragment direction of insertion on recombinant plasmid is correct;Realize D6D stabilization, permanent expression;Real-time fluorescence quantitative PCR shows that D6D expression improves 2 times or so;Through gas chromatography analysis, the GLA converted in bacterial strain is improved more than 3.3 times compared with wild strain;It was found that α MSH content increases in mice serum and vitals (liver, lung, spleen, kidney), particularly liver improves 3.24 times.
Description
Technical field
The present invention relates to gene engineering technology field, more particularly to a kind of rhodotorula glutinis recombinant bacterium of importing α-MSH polypeptides
Strain and its preparation method and application.
Background technology
Many unrighted acids are got over because of its extensive physiologically active and its important function in terms of human health, nutrition
Paid close attention to get over by people.
The building-up process of microbial grease is almost similar to animals and plants, and most important part is exactly the synthesis of aliphatic acid, main
There are two kinds of kytoplasm enzyme system catalysis, acetyl CoA carboxylase and fatty acid synthase complex, be that carbon source is passed through repeatedly using acetyl-CoA
Carbochain extends synthesizing saturated fatty acid, or again by desaturation synthesis unrighted acid.It is main during desaturation
It is responsible for catalysis by various desaturases, is the key for synthesizing long-chain unsaturated fatty acid, C=C can be introduced on fatty acid carbon chain
Double bond, the degree of unsaturation of aliphatic acid is improved, fatty acid desaturase is widely present in yeast.
And the enzyme for synthesizing unrighted acid is divided into two kinds, the fatty acid desaturase that methyl orientation and carboxyl orient.First
The fatty acid desaturase of base orientation introduces carbon-carbon double bond at the carbon atom that methyl end is fixed, and is referred to as ω-desaturase;Carboxylic
The fatty acid desaturase of base orientation introduces carbon-carbon double bond at the carbon atom that c-terminus is fixed, and is referred to as Δ (delta)-go to satisfy
And enzyme, it is also referred to as " front-end " desaturase.First carbon carbon double bond is introduced into saturated fatty acid by Δ 9- desaturases,
Second carbon-carbon double bond is responsible for introducing by Δ 12 and Δ 6- desaturases, and the desaturase of Δ 15 is then responsible for introducing the 3rd double bond.
After cell synthesizes 18C saturated fatty acids, stearic acid obtains oleic acid through stearoyl-CoA desaturase desaturations;Oil
Acid is catalyzed generation linoleic acid through Δ 12- desaturases, and alpha-linolenic acid (ALA) is synthesized through Δ 15- desaturases;Linoleic acid is through Δ 6-
Desaturase catalysis generation gamma-Linolenic acid GLA.Wherein, Δ 6- desaturases are the key enzymes in GLA route of synthesis, for the first time
It is to separate clone from blue-green algae within 1993 to obtain to clone Δ 6- desaturases, and obtaining GLA by biotechnology for the first time is
The Δ 6- delta 8 desaturase genes production GLA of blue-green algae was expressed in potato in 1996.GLA further dehydrogenations in human body extend shape
Into physiological activators such as arachidonic acid (AA), prostanoid and leukotrieneses, there is important physiological significance to human body, thus
In recent years people are higher to the research temperature of Δ 6- fatty acid dehydrogenase genes, also achieve greater advance.
Although having there is more reports to show, in yeast GLA contents can increase expression external source Δ 6- fatty acid dehydrogenases
Add, but so far, not yet occurring can be with the yeast strain of high yield gamma-Linolenic acid (GLA) using genetic engineering structure
Report.
Alpha-melanocyte stimulating hormone (α-melanocyte-stimulating hormone, α-MSH) is to belong to casting skin matter
Family, it is a kind of endogenous neural peptide derived from by POMC (POMC), by the small peptide of 13 Amino acid profiles,
Nature exists in the form of cation, is the precursor protein of all casting skin matter Hormone Peptides, is responsible for secreting, expressing by pituitary.To the greatest extent
Pipe α-MSH are as caused by pituitary, but have its figure in defense cell, peripheral tissues such as skin, illustrate that it is immune
Control characteristic.α-MSH physiological property illustrates its importance in immunity of organism particularly inherent immunity and in antibacterial
Aspect can also play a significant role.It is more widely at present its anti-inflammatory effect to α-MSH applications, because it can adjust many inflammation
Inflammation factor, illustrate that there are powerful anti-inflammatory properties.α-MSH have powerful inhibitory action to almost all kinds of inflammation, bag
The anti-inflammatory of acute inflammation, chronic inflammation, system inflammation, local inflammation, allergic inflammation and central nervous system is included, effect can
Played a role by maincenter, periphery in a variety of endocrines, immunological regulation system.But because α-MSH itself are there is also shortcoming, its
Half-life period is shorter, in vivo half-life period there was only more than 20 minutes, so existing administering mode is injection, and need to constantly inject to tie up
Drug effect is held, is made troubles to patient and painful, if directly oral polypeptide, internal gastral enzyme can be degraded, so needing
A kind of new Oral administration is developed to realize the application of this peptide.
The content of the invention
For insufficient existing for prior art described above, it is more that the first object of the present invention is to provide a kind of importing α-MSH
The rhodotorula glutinis recombinant bacterial strain of peptide.
The second object of the present invention is to provide the preparation method of the rhodotorula glutinis recombinant bacterial strain of the importing α-MSH polypeptides.
The third object of the present invention is to provide the application of the rhodotorula glutinis recombinant bacterial strain of the importing α-MSH polypeptides.
To solve above-mentioned technical problem, the present invention adopts the following technical scheme that:Import the rhodotorula glutinis weight of α-MSH polypeptides
Group bacterial strain, α-MSH polypeptides are imported in the rhodotorula glutinis GM4-D6D through the restructuring of Δ 6- delta 8 desaturase genes.
Δ 6- desaturases (D6D) are incorporated into rhodotorula glutinis GM4-D6D genome as expression vector.
The Δ 6- desaturases (D6D) are obtained by the D6D Gene Isolations of cunninghamella echinulata with amplification.
The rhodotorula glutinis construction method of Δ 6- delta 8 desaturase genes restructuring, the step of it includes, are as follows:
(1) expression vector pPGK1Z-rD-ME extracting;
(2) PGK1 genes and D6D genes are connected;
(3) PGK1-D6D fragments are reacted with the double digestion of expression vector carrier, are connected.
The step of method of expression vector pPGK1Z-rD-ME extracting, is as follows:
(1) bacillus coli DH 5 alpha containing pPGK1Z-rD plasmids is inoculated into equipped with 5mL LB-amp culture mediums, in 37
250rpm shaken cultivations are stayed overnight at DEG C;
(2) drawing 1.5mL, in centrifuge tube, 12000rpm is centrifuged 1 minute bacterium solution at 4 DEG C, abandons supernatant overnight;
(3) fluid nutrient medium in centrifuge tube is blotted with filter paper, bacterial sediment is suspended in 200 μ L STET buffer solutions,
Fully mix;
(4) lysozyme soln that 4mL is newly prepared is added, is mixed after standing 5 minutes at room temperature;
(5) centrifuge tube is placed in boiling water bath 45 seconds, 12000rpm is centrifuged 5 minutes at once after taking-up;
(6) sediment in picking centrifuge tube discards, and adds 8mL, 5%CTAB in the supernatant of centrifuge tube, uses blender
After mixing, 13000rpm is centrifuged 5 minutes, abandons supernatant, the liquid in centrifuge tube is blotted with filter paper;
(7) 1.2M NaCl 300mL are added, sediment is fully dissolved, adds 750mL pre-cooled ethanol, are fully mixed
Afterwards, 13000rpm is centrifuged 15 minutes, abandons supernatant;
(8) 70% cold ethanol of 1mL is taken, slowly elution centrifugation inside pipe wall, 13000rpm centrifugation 5min, supernatant is abandoned, with filter
Paper blots the liquid on tube wall, and putting makes nucleic acid precipitation spontaneously dry 5-10min in room temperature;
(9) sediment is dissolved in 50mL TE buffer solutions, and blender mixes, and is saved backup in -20 DEG C.
Connection PGK1 genes and the primers of D6D genes are:
PGK1-Bam HI primer1:
5′-CGCGGATCCTATTTAGATTCCTGACTTCAACTC-3′(Bam HI)
PGK1-XhoIprimer 2:
5′-TATCCGCTCGAGTGTTTTATATTTGTTGAAAAAGTAGATGTCGCCTATTATT-3′(XhoI)
D6D-XhoIprimer1:
5′-TCTGCTTTCTTCGCTCCGCTCGAGATGTCAGGGCAAACTCGAG-3′(XhoI)
D6D-XhoIprimer2:
5′-CATGCCATGGATCATCTAAAACATCTTTTGAGAG-3′(NcoI)
Rhodotorula glutinis and the mol ratio of D6D genetic fragments will be controlled 1:3-10.
A kind of preparation method of the rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides, including the step of it is as follows:
(1) preparation engineering bacterial strain GM4-D6D bacterial strain competent cells.
(2) totally 100 μ L after being mixed after FITC- α MSH that 10 μ g have been modified dissolving with competent cell, are added to 0.2cm
In the electricity conversion cup of precooling;
(3) electric shockization;
(4) after electric shock terminates, the 1M sorbitol solutions of 900 μ L precoolings are added into conversion cup immediately, is slightly inhaled and beaten with rifle
Mix, then gone in sterilized centrifuge tube, 30 DEG C of standing l h, the fresh YPD culture medium weights of 1mL are added after centrifugation
Outstanding thalline, 30 DEG C, 200rpm shakes 1 hour;
(5) bacterial strain finally obtained is respectively designated as GM4-D6D-F α MSH;
The electric shockization step is as follows:
(1) DNA to be transformed that the competent cell and 20 μ L (about 10 μ g) that oneself prepares by 80 μ L have linearized
Mixing, it is added in the electricity conversion cup of 0.2cm precoolings;
(2) by the electricity conversion cup ice bath 5min equipped with mixed liquor;
(3) parameter of electroporation is adjusted:Voltage 1.5kV, electric capacity 25uF, the Ω of resistance 200, electric shock the duration be about
5ms or so;
(4) after electric shock terminates, the 1M sorbitol solutions of 1mL precoolings are added into conversion cup immediately, slightly inhales to beat with rifle and mixes
It is even, then gone in sterilized centrifuge tube, 30 DEG C of standing l h, then YPD culture mediums fresh addition 1mL, 30 DEG C,
200rpm shakes 1 hour;
(5) 3000rpm at room temperature, 4min is centrifuged, thalline is resuspended with 200 μ L ddH2O;
(6) liquid that will disappear is coated on YPD flat boards (containing 50 μ L Zeocin), is placed in 30 DEG C of incubators and cultivates 2-3d, Zhi Daochang
Untill going out single bacterium colony.
The rhodotorula glutinis recombinant bacterial strain of the importing α-MSH polypeptides is used to treat inflammatory bowel disease medicine and feature food
Application in product preparation, can make biological capsule.Particularly be used to treat application in colitis medicine, can be aqua or
Person's pulvis.
The rhodotorula glutinis recombinant bacterial strain of the importing α-MSH polypeptides can be also used for the food or medicine related to MSH effects
Application in product preparation.
The present invention has the advantages that:Foreign gene D6D expression vector pPGK1Z-rD-D6D are successfully constructed, are passed through
Double digestion identifies that the purpose fragment direction of insertion on recombinant plasmid is correct;Recombinant plasmid is imported in rhodotorula glutinis, inverted bacterium
Strain PCR identifications, recombinant plasmid are successfully imported in rhodotorula glutinis and are inserted into the genome of rhodotorula glutinis, realize the steady of D6D
Fixed, permanent expression;Real-time fluorescence quantitative PCR shows that D6D expression improves 2 times or so;Through gas chromatography analysis, turn
The GLA changed in bacterial strain is improved more than 3.3 times compared with wild strain;The serum of the mouse of GM4-D6D- α MSH groups and liver Central Asia oil
Acid, gamma-Linolenic acid, arachidonic relative amount dramatically increase compared with Normal groups, GM4-D6D- α MSH wherein in blood
The GLA contents of group improve about 7.26 times compared with Normal groups, and arachidonic acid improves about 1.55 times;GM4-D6D- α in liver
The GLA contents of MSH groups improve about 4.33 times compared with Normal groups, and arachidonic acid improves about 1.28 times;Because GM4- itself
D6D- α MSH bacterial strains can produce more gamma-Linolenic acid, so Mouse oral can increase the content of the GLA in serum, simultaneously
It is probably because part gamma-Linolenic acid is to arachidonic that arachidonic acid, which increases, compared with control group, in GM4-D6D- α MSH groups
Acid conversion.
Brief description of the drawings
Fig. 1 is the Technology Roadmap of rhodotorula glutinis integrating expression vector pPGK1Z-rD-D6D structure;
Fig. 2 is colonial morphology figure observation photo;
Fig. 3 is the PCR amplified band figures of PGK1 (A) and D6D (B) gene;
Fig. 4 is that (wherein 1,2,3 attach most importance to for rhodotorula glutinis conversion bacterial strain GM4-D6D Insert Fragment D6D PCR detections figure
Group bacterial strain, 4,5,6 be empty carrier bacterial strain);
Fig. 5 is that recombinant plasmid pPGK1Z-rD-D6D double digestions qualification figure (is compareed, wherein 1 is with pPGK1Z-rD
PPGK1Z-rD-D6D, 2 be pPGK1Z-rD);
Fig. 6 is rhodotorula glutinis D6D gene expression dose figures;
Fig. 7 is that the polypeptide of Laser Scanning Confocal Microscope picture analyzing FITC marks is contaminated into the position oil droplet after intracellular with Nile red
Chromatic graph, wherein (A) red fluorescence channel, (B) green fluorescence channel, (C) A and B two open the stacking chart of figure;
Fig. 8 is concentration map of the electricity conversion into the polypeptide of intracellular;
Fig. 9 be the concentration of α-MSH in serum such as;
Figure 10 is α-MSH Tissue distribution figure;
Figure 11 is for the concentration curve of α-MSH in colon mucus;
Figure 12 is the activity of MPO in colon;
Figure 13 is cytokine-expressing figure in colon;
Figure 14 is colon's pathological section figure (100X).
Specific embodiment
In order to preferably illustrate present invention, illustrated below with some preferably specific embodiments.But these have
Body embodiment is simply to illustrate that present disclosure, rather than present invention is limited.2.1 experiment materials and instrument
Device explanation
2.1.1 strain
Rhodotorula glutinis (Rhodotorula glutinis) GM4 is through screening and preserving (CCTCC M 2012203);Wine brewing
Yeast (Saccharomyces cerevisiae) 2.1445 is purchased from China General Microbiological culture presevation administrative center
(CGMMCC);Cunninghamella echinulata (Cunninghamella echinulata) MIAN6;Escherichia coli (Escherichia
coli)DH5α。
2.1.2 plasmid
Expression vector pPICZ-rD, build and preserve.
2.1.3 culture medium and main agents
(1) YPD culture mediums (1L), YPD-zeocin culture mediums (1L), Luria-Bertani (LB) culture medium (1L), LB-
Ampicillin culture mediums (g/L), less salt LB-zeocin culture mediums, Potato dextrose agar (PDA) culture mediums (g/
L);
(2) STET buffer solutions, TE buffer solutions, 10%SDS;
(3) plasmid extraction liquid;
(4) 10xDNA buffer link buffer solution;
(5) Tricine SDS-PAGE electrophoresis reagents;
Negative pole cathode buffer liquid (10x), gel buffer liquid (3x), fixer, dyeing liquor, destainer, sample buffer,
AB-3 storing liquids (49.5%T, 3%C), AB-6 storing liquids (49.5%T, 3%C), 16% separation gel, 10% squeegee, 4% is dense
Contracting glue.
Above solution is by known existing fixing means configuration.
2.2.1 the separation and amplification of target gene
2.2.1.1 the separation and amplification of saccharomyces cerevisiae PGK1 genes
1st, separate:
Saccharomyces cerevisiae is inoculated in 50mL/250mL YPD fluid nutrient mediums, 30 DEG C, and 180rpm is cultivated to OD660When=3 from
The heart (12000r/min, 5min, 4 DEG C), supernatant is abandoned, collect thalline.Aseptic water washing thalline centrifuges afterwards twice, afterwards with cold sterilized water
Thalline is resuspended, bacteria suspension, which is gone in the mortar containing liquid nitrogen and 1g alumina, grinds broken somatic cells, then goes to 5mL DNA extractions
(50mM TRIS, 10mM MgCl in buffer solution2, 50mM NaCl, 1% (wt/vol) SDS, pH 7.4) centrifuge tube in.By
Phenol/chloroform extracting and methanol precipitation step, saccharomyces cerevisiae DNA repeatedly is separated.
2nd, PCR is expanded:
According to PGK1 gene orders, primer is designed:
- the CGCGGATCCTATTTAGATTCCTGACTTCAACTC-3 ' of forward primer 5 ' (Bam HI)
- the TATCCGCTCGAGTGTTTTATATTTGTTGAAAAAGTAG-3 ' of reverse primer 5 ' (XhoI)
PCR reactions are anti-by Takara PCR reaction kits operation (being purchased from precious bioengineering (Dalian) Co., Ltd) PCR
Answer condition:94 DEG C of 5min, 94 DEG C of 0.5min, 55 DEG C of 1min, 72 DEG C of 1min, 72 DEG C of 10min, 30 circulations, 5 μ L PCR are taken to expand
Product is treated to analyze through 2% agarose gel electrophoresis.
2.2.1.2 the separation and amplification of cunninghamella echinulata D6D genes
1st, separate:
The extraction operating process of cunninghamella echinulata total serum IgE uses Oligotex with reference to Wan and Zhang et al. method
MRNA Mini Kit (Qiagen) extract mRNA from total serum IgE.
2nd, PCR is expanded:
According to cunninghamella echinulata D6D gene orders (the GenBank accession number announced:
DQ177498), D6D primers are designed.
- the CCG of forward primer 5 'CTCGAGATGTCAGGGCAAACTCGAG-3′(XhoI)
- the CATG of reverse primer 5 'CCATGGATCATCTAAAACATCTTTTGAGAG-3′(NcoI)
3rd, reverse transcription (RT) is reacted:
(1) reverse transcription is by Takara reverse transcription reagent box operation (being purchased from precious bioengineering (Dalian) Co., Ltd);
(2) 37 DEG C are reacted 1 hour;
15 minutes terminating reactions of (3) 75 DEG C of incubations, it is stored in -20 DEG C or is directly used in downstream experiment.
4th, PCR reacts:
PCR reactions are anti-by Takara PCR reaction kits operation (being purchased from precious bioengineering (Dalian) Co., Ltd) PCR
Answer condition:94 DEG C of 5min, 94 DEG C of 0.5min, 55 DEG C of 1min, 72 DEG C of 1min, 72 DEG C of 10min, 30 circulations, 5 μ L PCR are taken to expand
Product is treated to analyze through 2% agarose gel electrophoresis.
2.2.1.3 gel electrophoresis is reclaimed with PCR primer
1st, gel electrophoresis:
Operated according to gel electrophoresis Conventional procedures.
2nd, PCR primer reclaims:
Go out target DNA band using ultraviolet photodevelopment, cut corresponding agar band with slicer, insert in centrifuge tube;Tool
The operation of body is:Binding Buffer II (7~4 μ l/1mg agar gels) are added, are shaken up in 60 DEG C of water-baths, until completely
Dissolving;Put the agar gel of dissolving into UNIQ-10 pillars 5min, filtrate, the centrifugation of 8000rpm normal temperature are collected with collecting pipe
15min;The waste liquid of collection is discarded, removes UNIQ-10 posts, enters 600 μ l Wash Solution, 8000rpm centrifugations 2min;Repeat
The waste liquid of collection is discarded, removes UNIQ-10 posts, enters 600 μ l Wash Solution, 8000rpm centrifugations 2min;Take out UNIQ-
10 posts are put in new centrifuge tube, add 40 μ l Elution Buffer in pillar film center, 5min is placed in 50 DEG C;Room temperature
Lower 12000rpm centrifuges 1min, and liquid is to reclaim DNA, -20 DEG C freeze it is standby.
2.2.2 external source D6D integration vectors pPGK1Z-rD-D6D structure is expressed
2.2.2.1 integration vector pPGK1Z-rD-D6D structure route map
D6D gene integration expression vectors are designed using homologous recombination principle, constructing technology route is shown in Fig. 1:
2.2.2.2 expression vector pPGK1Z-rD-ME extracting
PPGK1Z-rD plasmids are what this laboratory built and preserved, are extracted according to conventional plasmid extraction step.
2.2.2.3 over-lap PCR connects PGK1 and D6D
Overlap PCR primers for PGK1 and D6D are as follows:
PGK1-Bam HI primer1:
5′-CGCGGATCCTATTTAGATTCCTGACTTCAACTC-3′(Bam HI)
PGK1-XhoIprimer2:
5′-TATCCGCTCGAGTGTTTTATATTTGTTGAAAAAGTAGATGTCGCCTATTATT-3′(XhoI)
D6D-XhoIprimer1:
5′-TCTGCTTTCTTCGCTCCGCTCGAGATGTCAGGGCAAACTCGAG-3′(XhoI)
D6D-XhoIprimer2:
5′-CATGCCATGGATCATCTAAAACATCTTTTGAGAG-3′(NcoI)
PGK1 and D6D fragments, using PGK1 the and D6D fragments of recovery as co-template, PGK1-Bam are reclaimed after 5 circulations
HI primer1 and D6D-XhoIprimer2 are that upstream and downstream primer carries out Overlap PCR, obtain PGK1-D6D fragments.
Erlap PCR reactions (are purchased from precious bioengineering (Dalian) limited public affairs by the operation of Takara PCR reaction kits
Department) .PCR reaction conditions:94 DEG C of 5min, 94 DEG C of 0.5min, 55 DEG C of 1min, 72 DEG C of 1min, 72 DEG C of 10min, 30 circulations.
2.2.2.4 the reaction of the double digestion of PGK1-D6D fragments and carrier, connection
The 1st, Overlap PCR primers and pPGK1Z-rD are carried out to NcoI and Bam HI double digestions respectively
Plasmid pPGK1Z-rD NcoI/Bam HI double digestion reaction systems:
Plasmid pPGK1Z-rD-ME:15 μ l, NcoI restriction endonucleases:2 μ l, Bam HI restriction endonucleases:2 μ l,
10×buffer:5 μ l, 1%BSA:5 μ l, ddH2O:26μl.
Fragment PGK1-D6D NcoI/Bam HI double digestion reaction systems:
Fragment PGK1-D6D:10 μ l, NcoI restriction endonucleases:2 μ l, Bam HI restriction endonucleases:2 μ l,
10×buffer:5 μ l, 1%BSA:5 μ l, ddH2O:26μl.
Endonuclease reaction was in 37 DEG C of water-baths 3 hours.
2nd, coupled reaction
After endonuclease reaction, construction recombination plasmid pPGK1Z-rD-D6D.
Coupled reaction reaction system is as follows:
Fragment PGK1-D6D digestion purified products:6 μ l, carrier pPGK1Z-rD digestion purified products:2 μ l, 10 × T4
DNALigase Buffer:1 μ l, T4 DNA ligases:1μl.
The mol ratio of 16 DEG C of water-bath reaction overnights, carrier and exogenous dna fragment will be controlled 1:3-10.
2.2.3 recombinant plasmid pPGK1Z-rD-D6D electricity conversion rhodotorula glutinis competent cell
2.2.3.1 the preparation of rhodotorula glutinis competence
Picking yeast single bacterium colony is seeded in 5mL YPD fluid nutrient mediums, and in 30 DEG C, 250rpm shaken cultivations are stayed overnight;With 1%
Inoculum concentration is forwarded to 100mL YPD fluid nutrient mediums, in 30 DEG C, 250rpm shaken cultivations to cell OD600 ≈ 1.4;Bacterium solution is in 4
DEG C, 3000g centrifugation 5min sedimentation cells, supernatant is abandoned, is resuspended with 100mL sterilized waters;It is repeated once;4 DEG C, 3000g centrifugations 2min
Sedimentation cell, supernatant is abandoned, cell is resuspended with the 1M sorbierites of 20mL ice precoolings;4 DEG C, 3000g centrifugation 2min sedimentation cells, abandon
Clearly, cell is resuspended with 200 μ L 1M sorbierites, for converting.
2.2.3.2 plasmid linearization
About 10 μ g recombinant plasmids pPGK1Z/rD/D6D are subjected to single endonuclease digestion with Sac I.
Digestion system is as follows:
Sac I:1 μ l, 10 × buffer:5 μ l, plasmid pPGK1Z-rD-D6D:10 μ l, ddH2O:7μl.
2.2.3.3 electricity conversion
By the recombinant plasmid linearized electricity conversion to rhodotorula glutinis GM4, electric step of converting is according to conventional electric method for transformation
Operation.
2.2.3.4 recombinate the PCR detections of rhodotorula glutinis
(1) the preferable single bacterium colony of growing way is transferred in YPD fluid nutrient mediums in picking YPD resistant panels, 30 DEG C, 250rpm
Shaken cultivation is to OD600 more than 2;
(2) take 1mL bacterium solutions 12000rpm to centrifuge 2min, abandon supernatant, add 100 μ L TE buffer solutions and thalline is resuspended, water-bath is boiled
5-10min is boiled, -20 DEG C of refrigerators is immediately placed on and freezes 15min, stand dissolves bacteria suspension at room temperature, 12000rpm centrifugation 5min,
The μ L of supernatant 5 are taken to enter performing PCR detection for template.PCR reactions (are purchased from precious bioengineering by the operation of Takara PCR reaction kits
(Dalian) Co., Ltd) PCR reaction conditions:94 DEG C of 5min, 94 DEG C of 0.5min, 55 DEG C of 0.5min, 72 DEG C of 1.5min, 72 DEG C
5min, 30 circulations.
2.2.3.5 the digestion verification of plasmid
After bacterium solution PCR preliminary identifications, the plasmid in correct positive colony is extracted, distinguishes counterweight with Nco I and Bam HII
Group plasmid carries out double digestion identification, and reaction temperature is 37 DEG C.
Endonuclease reaction system is as follows:
Plasmid:2 μ l, 10 × buffer:4 μ l, NcoI:1 μ l, BamHII:1 μ l, ddH2O:41μl.
2.2.3.6 transformant Detection of Stability
Rhodotorula glutinis transformant is inoculated in 40mL YPD fluid nutrient mediums, 30 DEG C, 250rpm shaken cultivations 24h-
36h.1mL bacterium solutions are taken to be diluted to 10 respectively with sterilized water-2,10-3,10-4, respectively take the dilution of 200 μ L difference dilution factors to apply respectively
Common YPD flat boards and YPD-Zeocin resistant panels are distributed in, clump count is calculated, is designated as total bacteria count respectively and with integrated plasmid
Clump count.YPD fluid nutrient mediums are forwarded to 1% inoculum concentration, 30 DEG C, 250rpm shaken cultivations, using 24h as 10 generations, trained altogether
Support 50 generations.A plate count is carried out from generation to generation every 10.
Calculate plasmid stability:Stability (%)=clump count ÷ total bacteria count × 100% with integrated plasmid.
2.2.4 transformant D6D expressions determine
Real-time fluorescence quantitative PCR detects expressions of the D6D in bacterial strain is converted.Wild strain GM4 and conversion bacterial strain
GM4-D6D is collected in YPD culture mediums after fermentation 24h, 48h, 72h respectively, extraction wild strain and the total serum IgE for converting bacterial strain,
Method is with reference to above 2.2.1.3;CDNA is obtained through reverse transcription, method is with reference to 2.2.1.3.CDNA after synthesis is diluted 30 times,
Instruct to carry out according to fluorescence quantitative kit SYBR PrimeScript TM RT-PCR Kit.
D6D real-time fluorescence quantitative PCR primer is:
F:5′-ATGTCAGGGCAAACTCGAG-3′;R:5′-ATCATCTAAAACATCTTTTGAGAG-3′
Quantitative fluorescent PCR is examined (limited purchased from the rich day science and technology in Hangzhou according to BioRT real-time fluorescence RT-PCRs kit method
Company)
PCR amplification conditions are:95 DEG C of 3s, 95 DEG C of 5s, 60 DEG C of 31s, 40 circulations.Simultaneously to Real-time PCR primers
SYBR melting curve analysis is carried out, each sample is parallel to do 4 secondary responses, repeats experiment 2 times, and with reference to Pfaffl (2001) side
Method carries out data analysis.
2.2.5 bacterial strain GM4-D6D fatty acid compositional analysis are converted
1st, the extraction of bacterial strain GM4-D6D total fatty acids
The GM4-D6D bacterial strains of stationary phase are collected, are cleaned twice with distilled water after centrifugation, 5000g centrifuges 5min in 4 DEG C and collected
Constant weight is dried to after thalline, grind into powder, bacterium powder is wrapped with filter paper and is dried to constant weight again;The bacterium powder that filter paper wraps up is put in
In extracting barrel, injection absolute ether submergence sample, backflow extracting 8h or so in 70 degree or so of water bath with thermostatic control, after removing solvent
Grease it is stand-by;Add 1mL 2% (wt/vol) sulfuric acid-methanol, 60 DEG C of esterification 2h;1mL hexanes are added after cooling, are vortexed
10min;The μ L of step ethane 800 are taken to be added to progress GC analyses in vial.
2nd, GC is analyzed
Match somebody with somebody hydrogen flameionization (FID) detector and capillary chromatographic column HP-INNOWAX with Bruker 450-GC instruments
(30m×0.25mm).Qualitative and quantitative analysis is carried out to different aliphatic acid according to GC routine operations.
As a result prove
2.3.1 the colonial morphology of rhodotorula glutinis
After rhodotorula glutinis GM4 grows 3 days on Bangladesh's flat board, form such as Fig. 2.Bacterium colony 3~5mm of average diameter, color
For red or Chinese red, gloss, surface is smooth and neat in edge, rounded projection.
2.3.1 PCR augmentation detection purpose fragments
Design specific primer enters performing PCR amplification to know the real situation gene PGK1 and D6D, is analyzed by agarose gel electrophoresis, Fig. 3
In (A) be shown in 800bp or so and amplify purpose band, (B) is shown in 13000bp or so and amplifies purpose band in Fig. 3.
Recombinant plasmid is imported into rhodotorula glutinis competent cell by electrotransformation, the cell pyrolysis liquid of rhodotorula glutinis is entered
Performing PCR detects, and enters performing PCR amplification with target gene D6D specific primer, is analyzed by agarose gel electrophoresis, Fig. 5 is shown
1st, 2,3 passages (recombinant bacterial strain) amplify purpose band in 13000bp or so, and negative control (empty carrier bacterial strain, i.e., it is wild viscous red
Yeast strain GM4, without recombinant plasmid transformed) then without band.Illustrate that recombinant plasmid pGK1Z-rD-D6D is successfully transferred to viscous red ferment
Mother is simultaneously inserted into rhodotorula glutinis genome.
Recombinant bacterium GM4-D6D extracts plasmid after culture, is imaged by EcoRI and HindIII double digestions rear electrophoresis,
As a result such as Fig. 4, it can be seen that have band (passage 1) in 2100bp and 3100bp or so, the clip size after digestion and inserted
Target gene clip size is consistent, and illustrates that the direction of insertion of target gene fragment on recombinant plasmid is correct.
2.3.2 recombinant plasmid stability detects
In order to detect recombinant plasmid pPGK1Z-rD-D6D genetic stability, we are to conversion bacterial strain in non-selection pressure
Lower Shaking culture 60 from generation to generation, picks bacterium solution in being coated with, cultivating in Zeocine resistant panels, calculates clump count.As a result such as table 2-1
It is shown, the rhodotorula glutinis bacterial strain of conversion is shown after continuously 60 generations of culture, and stability still can reach 99.31%, show
Under non-selection pressure, the plasmid in rhodotorula glutinis has good genetic stability.
The Detection of Stability of table 2-1 recombinant plasmids
2.3.3 rhodotorula glutinis bacterial strain D6D expression analysis is converted
The result of real-time fluorescence quantitative PCR analysis D6D gene transcription levels is shown in Fig. 6, and the D6D expressions for converting bacterial strain are
2 times or so of wild strain, wild strain D6D transcriptional levels drop to reduced levels after cultivating 72 hours, and convert bacterial strain and exist
It grows and gamma-Linolenic acid expression phase, its D6D transcriptional level are all higher than wild strain always.D6D high transcriptional level can
With can for gamma-Linolenic acid and synthesis provide needed for enough enzymes so that the synthetic quantity of gamma-Linolenic acid maintain it is higher
Level.
2.3.4 the accumulation research of gamma-Linolenic acid
The GLA of higher level whether can be produced in order to be overexpressed the rhodotorula glutinis of D6D genes conversion bacterial strain, in experimentation
Its fatty acid composition is determined and analyzed, it is found that the GLA contents of conversion bacterial strain significantly increase, is carried by original 3.12%
It is high that to 10.36%, while the content of the substrate linoleic acid of GLA synthesis substantially reduces, it can thus be seen that with wild strain phase
Than conversion bacterial strain can accumulate more GLA.
Table 2-2 converts the aliphatic acid composition of bacterial strain and wild strain
In the present invention, Δ 6- fatty acid desaturases are the rate-limiting enzymes of synthesis of long-chain polyunsaturated fatty acids, respectively in n-3
Oleic acid (LA) dehydrogenation generation GLA being catalyzed in approach in ALA dehydrogenations generation SDA and n-6 approach.Closed in the biology of gamma-Linolenic acid
During, LA the 6th carbon atom dehydrogenation is changed into GLA by △ 6- fatty acid desaturases.Constantly exerted by researchers
Power, the encoding gene for having had many GLA key enzymes are cloned and realize functional verification, and some genes are also utilized
In the modification of fatty acid metabolism approach, and obtain ideal effect.Such as Laoteng is successfully separated the Δ 6- fat in Mucor rouxii
Fat acid desaturase, it is found that it has the similitude of height in the Δ 6- fatty acid desaturases of plant, and make it in saccharomyces cerevisiae
It is middle successfully to be expressed;He Lu et al. have found that substantial amounts of GLA is had in the fermentation process of fermented soya bean to be produced, therefore isolate height
GLA rhizopus is produced, and therefrom clone obtains Δ 6- desaturase genes, being expressed in saccharomyces cerevisiae can cause GLA's
Accumulation;Δ 6- fatty acid desaturases in cunninghamella echinulata bacterium are expressed in tangerine woods saccharomyces oleaginosus by Wang Ping et al., are made
Its GLA content accounts for the 1.2% of total fatty acids.And in this experiment, by fatty acid analysis, it is found that the LA in conversion bacterial strain is obvious
Less than wild strain, this can also reflect LA from side and further synthesize GLA through D6D catalysis, so that in conversion bacterial strain
LA content reduces, and GLA content increases.
Rhodotorula glutinis is the blast resistance of a plant height Lipid-producing, standing to be used for producing microbial grease and unsaturated fat
Acid, carotenoid etc..This laboratory screens one plant of production fat ability stronger rhodotorula glutinis early stage, and its fat content can be up to
22.54%.In this experiment, we make use of the rhodotorula glutinis expression plasmid construction work of this laboratory early stage, successfully build
Integrating expression vector pPGK1Z-rD-D6D, two rDNA fragments containing rhodotorula glutinis and saccharomyces cerevisiae is strong on the carrier
Promoter PGK1, the stable high copy expression of target gene is realized using rDNA as integration site, so as to which external source is pierced into small gram of silver of spore
The D6D gene integrations of Chinese mould can be stablized, high efficient expression on the chromosome of rhodotorula glutinis, as a result show and pass on 60
Dai Hou, plasmid remain to be stable in the presence of in transformant, and the D6D expressions of rhodotorula glutinis conversion bacterial strain are apparently higher than wild
Bacterial strain, its GLA yield also significantly improve.
Generally speaking, the present invention successfully constructs foreign gene D6D expression vector pPGK1Z-rD-D6D, is reflected through double digestion
Fixed, the purpose fragment direction of insertion on recombinant plasmid is correct;Recombinant plasmid is imported in rhodotorula glutinis, inverted bacterial strain PCR mirror
Fixed, recombinant plasmid is successfully imported in rhodotorula glutinis and is inserted into the genome of rhodotorula glutinis, realizes D6D stabilization, permanent
Expression;Real-time fluorescence quantitative PCR shows that D6D expression improves 2 times or so;Through gas chromatography analysis, bacterial strain is converted
In GLA improved compared with wild strain more than 3.3 times.
The rhodotorula glutinis engineering bacteria and allogenic polypeptide for introducing allogenic polypeptide prepare material in the positioning of intracellular
3.1.1 test strain
Rhodotorula glutinis recombinant bacterial strain GM4-D6D
3.1.2 culture medium
Same 2.1.2
3.1.3 main agents
0.5mg/mL Nile red coloring agent;α-the MSH and H22LP of FITC and Plam modifications
The method for introducing allogenic polypeptide
3.2.1 electroporation method mediation allogenic polypeptide enters GM4-D6D intracellulars
1st, preparation engineering bacterial strain GM4-D6D bacterial strain competent cells, the same 2.2.3.1 of method.
2nd, totally 100 μ L after being mixed after FITC- α MSH and FITC-H22LP that 10 μ g have been modified dissolving with competent cell,
It is added in the electricity conversion cup of 0.2cm precoolings;
3rd, electric shock process routinely operates;
4th, the bacterial strain finally obtained is respectively designated as GM4-D6D-F α MSH and GM4-D6D-FH22LP;
5th, α-MSH are transferred to GM4-D6D intracellulars by electroporation, obtain bacterial strain GM4-D6D- α MSH.
3.2.2 laser co-focusing detects polypeptide in the position of intracellular
0.1mL GM4-D6D-F α MSH and GM4-D6D-FH22LP bacterium solutions are taken respectively in 1.5mL EP pipes, 3000rpm from
Heart 5min, it is resuspended with 0.1mL distilled water, adds a few drop Nile red dyes, 2-3min is kept in dark place, it is then burnt micro- by being copolymerized
Mirror (TCS SP2) is observed.Green fluorescence 488nm lasing light emitter is observed, observes red fluorescence with 514 nanometers of lasing light emitter.
3.2.3 sepectrophotofluorometer quantitative analysis
(1) FITC- α MSH and FITC-H22LP concentration gradient titer are prepared;And 1mL titers are taken to 1 milliliter of colorimetric
Ware, fluorescence intensity Fs to be determined;1 milliliter of GM4-D6D-F α MSH and GM4-D6D-FH22LP bacterium solution is pipetted to 1 milliliter of cuvette,
Fluorescence intensity Fx to be measured;Blank solution is prepared in 1 milliliter of cuvette, fluorescence intensity F0 to be measured;
(2) standard curve between (Fs-F0) and testing sample standard concentration C is done;According to (Fx-F0) from standard curve
On try to achieve the content of sample.
(3) data analysis
Data analysis uses GraphPad Prism 5.0, and statistics is represented with Mean ± SD, the otherness between group point
Analysis uses single factor test variance (one-way ANOVA).
3.3 experimental result
3.3.1 the method validation polypeptide of Laser Scanning Confocal Microscope (CLSM) enters the position of intracellular
In order to detect polypeptide whether enter intracellular and they in the position of intracellular, contaminated with hydrophobic fluorescence material Nile red
Material dyeing fat drips are as shown in fig. 7, respectively using red and green fluorescence channel then respectively it can be seen that the fat drips that Nile red dyes
With aobvious green polypeptide FITC-F α MSH and FITC-FH22LP, and two figures are superimposed, it is found that red and green phosphor dot is complete
Full weight closes (green fluorescence point is smaller than the phosphor dot of red), is in yellow after superposition, it is same to show that two kinds of materials are present in
In individual nano-particle.This can be explained two kinds of polypeptides and is incorporated into intracellular, and because the lipotropism of itself is entered in fat drips.
3.3.2 fluorescence spectrophotometry intracellular polypeptide FITC- α MSH and FITC-H22LP content
After electricity conversion, we centrifuge away the polypeptide in solution, bacterium solution are collected, with fluorescence spectrophotometry intracellular
Polypeptide FITC- α MSH and FITC-H22LP content, from figure 8, it is seen that the concentration difference of two kinds of polypeptides is little, it is 3mg/
ML or so, and initially electricity conversion when polypeptide concentration be 10mg/mL, illustrate electricity conversion after intracellular polypeptide concentration reach initially
The 1/3 of concentration, and two kinds of polypeptides do not have significant difference in the concentration of intracellular.
Allogenic polypeptide is made it into rhodotorula glutinis GM4-D6D intracellulars by us by the method for electroporation, obtains bacterial strain
GM4-D6D-F α MSH and GM4-D6D-FH22LP because we to have polypeptide fat-soluble, from the figure of laser co-focusing
It can be seen that they are entered in the oil droplet of rhodotorula glutinis, while pass through fluorescence spectrophotometry intracellular polypeptide FITC- α
MSH and FITC-H22LP content, find more 1/3 allogenic polypeptide can be transferred into rhodotorula glutinis by the method for electroporation
Intracellular, and the maximum that Mark et al. is rotated into bovine serum albumin(BSA) in red blood cell using the method for electroporation is 1/4;And two
The content difference that kind of polypeptide is entered by electroporation after intracellular is little, is 3 μ g/mL, illustrates that the method is also applied for polypeptide
Conversion enters rhodotorula glutinis intracellular.
Once there is article to report that as the carrier of vaccine, micro-capsule is fabricated to as natural lipid with by yeast for oral viable yeast
Body packaging medicine, or the yeast of oral killed transmit polyunsaturated fatty acid, and yeast is acting as natural biological glue herein
The role of capsule, the transport of medicine and unrighted acid etc. can be realized by oral whole yeast.
Generally speaking, the present invention makes FITC- α MSH and FITC-H22LP enter rhodotorula glutinis by the method for electroporation
GN4-D6D intracellulars;Laser co-focusing experiment proves that two kinds of polypeptides are entered in oil droplet;Fluorescence spectrophotometry intracellular polypeptide
FITC- α MSH and FITC-H22LP content, finding the content of two kinds of peptides does not have significant difference, and is the 1/3 of primary quantity.
Healthy mice In vivo study
4.1 experiment materials and instrument
4.1.1 experimental strain
Bacterial strain GM4-D6D- α MSH and GM4-D6D
4.1.4 experiment mice
15 SPF level BALB/c mouses, buy in Zhongshan University's Experimental Animal Center.
4.2 experimental method
4.2.1 GM4-D6D- α MSH mouse In vivo study
4.2.1.1 concentration of the α-MSH in serum
1st, mice group
(1) GM4-D6D- α MSH groups, 6;
(2) GM4-D6D groups, 6 as control;
2nd, eyeball of mouse takes blood
The 1st, 3,5,7 day after feeding, eyeball rear vein beard blood taking method took blood (once take a blood sample 0.2mL).
3rd, α-MSH concentration in serum is surveyed
2500rpm centrifuges 15min, and the standard items for taking debita spissitudo to be 300pg/mL are diluted to a series of the dilute of concentration gradients
Release liquid;α-MSH concentration in serum is surveyed with ELISA kit, operating method follows ELISA kit explanation.
4.2.1.2 α-MSH Tissue distributions
Above-mentioned mouse by 7 days administration and after taking blood, mouse cervical dislocation is put to death at the 7th day, take respectively liver,
Spleen, lung, kidney, related adipose tissue and connective tissue above it are removed, normal saline flushing is clean, will organize to inhale with filter paper
It is dry;Clip is organized in right amount, 1mL physiological saline is added after being precisely weighed homogenate is made;The sample of homogenate is made in 200rpm, 25 DEG C
Lower concussion 20min, then centrifuges 15min under 25000rpm;Supernatant is crossed into 0.22 μm of miillpore filter, used after removing magazine
ELISA kit surveys α-MSH concentration, and method is same as above.
4.2.2 serum and liver fat acid constituents measure
4.2.2.1 mice group
GM4-D6D- α MSH groups, take 6 normal mouses, daily except normal feed is fed, also feed GM4-D6D- α MSH
Bacterial strain, every daily scale of feeding is 1 × 1010CFU;Normal groups, take 6 normal mouses, only feed daily normal feed and
The physiological saline of equal volume, as control.
4.2.2.1 determination of fatty acid in serum
In feeding 7 days, mouse took blood by eyeball, by blood serum sample formicester after centrifugation, took supernatant to carry out GC- after processing
MS is analyzed, the same 2.2.5 of method.
4.2.2.2 determination of fatty acid in liver
Mouse equally is put to death in the 7th day cervical dislocation, takes 80mg livers, adds chloroform:Methanol=2:1 extractant,
Moved into after homogenate in centrifuge tube, 25000rpm centrifugation 15min, precipitation is repeated once extraction process, and merging centrifuges supernatant twice.Add
Enter the 1.45mM of 0.2 times of volume NaCl solution, remove a layer nitrogen drying, esterification handles same blood serum sample.
4.2.3 data processing
Data processing and mapping use GraphPad Prism 5.0, and statistics is represented with average ± standard deviation, group
Between contrast use one-way analysis of variance (one-way ANOVA), the data analysis between two groups uses Student ' s
Test, p<0.05 is considered significant difference be present between group.
4.3 experimental result
4.3.1 detections of the α-MSH in serum and tissue
In order to detect GM4-D6D- α MSH deliveries α-MSH effect, after we make mouse take GM4-D6D- α MSH, the
1st, blood was taken by eyeball in 3,5,7 days, the concentration of α-MSH in serum is detected with ELISA kit, the mouse for taking GM4-D6D makees
Control.As illustrated, in GM4-D6D- α MSH groups, contents of the α-MSH in serum increases with the increase for taking number of days,
1 to 5 day, α-MSH content linearly increased, and after 5 days, hardly increases and is intended to steadily, and in GM4-D6D
Group, α-MSH content are always maintained at poised state, and contents of the GM4-D6D- α MSH groups α-MSH in serum in finite concentration
It is significantly higher than GM4-D6D groups (p<0.05).
From mouse tissue distribution map (Figure 10), GM4-D6D- α MSH deliveries α-MSH make it in liver, lung, spleen, kidney
Distribution dramatically increases, and is especially improved in the distributed density of liver by 5.35pg/g to 17.36pg/g, improves 3.24 times, and almost
Do not enter cardiac muscular tissue.This is probably that we guess that α-MSH are likely to fat with lipid mainly the reason for the liver metabolism
Matter forms chylomicron and is carried, and enters lymphatic system together, finally enters blood, is transported to each tissue of body, especially
It is the major organs liver of lipid-metabolism.
4.3.2 Analysis of Fatty Acids Composition
Can be seen that from the data in table 4-1 the mouse of GM4-D6D- α MSH groups serum and liver Linoleic acid, γ-
Leukotrienes, arachidonic relative amount dramatically increase compared with Normal groups, the GLA of GM4-D6D- α MSH groups wherein in blood
Content improves about 7.26 times compared with Normal groups, and arachidonic acid improves about 1.55 times;GM4-D6D- α MSH groups in liver
GLA contents improve about 4.33 times compared with Normal groups, and arachidonic acid improves about 1.28 times.Because GM4-D6D- α MSH itself
Bacterial strain can produce more gamma-Linolenic acid, so Mouse oral can increase the content of the GLA in serum, while and control group
Compare, it is probably because part gamma-Linolenic acid converts to arachidonic acid that arachidonic acid, which increases, in GM4-D6D- α MSH groups.
Table 4-1 serum fatty acid constituent analysis tables (%)
Table 4-2 liver fat acid constituent analysis tables (%)
Anti-inflammatory activity evaluation experimental proves
5.1 experiment material
5.1.1 culture medium and preparation of reagents
(1) LPS (lipopolysaccharides) solution, RMPI-1640 nutrient solutions;
(2) protease inhibitors, electricity turn buffer solution, lysate, transferring film liquid, glycine running buffer, PBST;
Above reagent, is prepared according to a conventional method.
5.2 experimental method
5.2.1 PBMC (PMNC) separation
The blood 36ml of healthy volunteer is extracted into centrifuge tube, adds 4ml ACD anti-coagulants;It is slowly added to close to tube wall
72ml lymphocyte separation mediums, 2000rpm centrifuges 15min at 25 DEG C;The white single core of the second layer is drawn with syringe
Cell;The mononuclearcell of absorption is placed in new test tube, measures volume, the lymphocyte separation medium of equivalent is added, 25
1500rpm centrifuges 10min at DEG C, collects mononuclearcell, repeats 5 times;The mononuclearcell being collected into is used and contains 10%
The RMPI-1640 nutrient solutions of hyclone are resuspended, and take and are dyed on a small quantity with trypan blue dye liquor, (dead in micro- Microscopic observation cell
Cell is blue, and living cells is colourless);Calculate cell viability (cell viability=viable count/TCS x100%);By cell
Auto-regulating System of Density of Heavy Medium is 1x106/ml, and constant incubator culture is standby.
3.2.2 the PBMC that recombinant bacterium cell culture supernatant processing LPS is stimulated
(a) DMEM buffer culture medium cultures 10h bacterial culture fluid is taken, 3000rpm centrifugations 10min, discards bacterium under normal temperature
Body, supernatant is collected, it is degerming with 0.22 μm of membrane filtration partly with after 3 μ g/ml furin digestions, collect filtrate;
(b) with the α-MSH concentration in α-MSH ELISA kits detection recombinant bacterium culture supernatant, α-MSH concentration is used
DMEM buffer culture mediums are adjusted to 80pg/ml, and the supernatant of other non-recombinant bacterium also dilutes identical multiple;
(c) PBMC cells are inoculated in Tissue Culture Plate by every hole 1ml, remove culture medium before experiment, added after starting
It is above-mentioned that the bifid bacterium culture supernatant after one times is diluted with the RMPI-1640 nutrient solutions for concentrating one times.Test and be divided into six ancestrals, every group
If 5 multiple holes.Normal group (N groups), only replacing PBS solution dilutes one times of RMPI-1640 nutrient solution of concentration to the group in an experiment;
LPS groups, replacing PBS solution dilute 1h after one times of RMPI-1640 nutrient solution of concentration, and 8 are stimulated with final concentration of 5 μ g/ml LPS
Hour;PDG7 groups (empty carrier group), after discarding culture medium, add after diluting one times with the RMPI-1640 nutrient solutions for concentrating one times
Empty carrier bifid bacterium culture supernatant be incubated 1h, afterwards with final concentration of 5 μ g/ml LPS stimulation 8 hours;pDG7+Furin
Group, identical with pDG7 group processing, simply bifid bacterium culture supernatant digests by furin;PBDMSH groups, with pDG7 groups
It is the rhodotorula glutinis recombinant bacterial strain for the importing α-MSH polypeptides for secreting α-MSH unlike processing;PBDMSH+Furin groups,
1h, Zhi Houyong are incubated with the rhodotorula glutinis recombinant bacterial strain culture supernatant of the importing α-MSH polypeptides digested by furin
Final concentration of 5 μ g/ml LPS is stimulated 8 hours;α-MSH groups are used as control for the α-MSH of synthesis.
5.2.3 Western Blot detect the expression of NF- kB proteins
A. total protein extraction
Cell after collection processing, is moved in centrifuge tube, and 4000rpm centrifuges 8min at 4 DEG C, removes supernatant, is added
Ice-cold PBS liquid washs 3 times, and 4000rpm centrifuges 8min again at 4 DEG C, removes supernatant, is placed at once cold on ice
Freeze;The mixed liquor of cell pyrolysis liquid and protease inhibitors is added, is blown and beaten with strength, 12000rpm is in 4 DEG C after placing 0.5h on ice
Lower centrifugation 10min, supernatant is transferred in another clean centrifuge tube, using BCA methods measure protein content, it is standby or-
80 DEG C of preservations;Sample total protein content is 100~150 μ g or so, take albumen sample-loading buffer and and supernatant, in 1/3 ratio
Mix, boiling water water-bath 15min makes albuminous degeneration, in standing 10min on ice, cools down rear electrophoresis.
B. electrophoresis
Running gel is prepared according to a conventional method.
When starting electrophoresis, voltage maintains 100v, and (2h is taken around) when going to separation gel etc. bromophenol blue, and voltage is improved
To 150v, when electrophoresis to bromophenol blue is reached at the top of separation gel, stop electrophoresis, prepare transferring film.
C. routinely operating method carries out transferring film to transferring film.
D. immune detection
Film is cleaned 3 times, each 10min with PBST, is placed in containing in confining liquid, vibrates closing on decolorization swinging table at room temperature
1h;Primary antibody dilutes is incubated a night at 1000 times, 4 DEG C on decolorization swinging table, cleans;Secondary antibody dilutes 1000 times, decolorization swinging table under normal temperature
Upper incubation 1.5h;Film is soaked in eluent, 55 DEG C of baking boxs are incubated 30min, are cleaned 3 times with PBST, each 10min;Into
As being imaged in system, gray scale is analyzed with image J.
3.2.4 detect culture supernatant TNF-α secretion
The post-stimulatory culture supernatants of LPS are collected, 3000rpm centrifugation 15min, collect supernatant, employment double-antibody sandwich
The concentration of TNF-α, its step operate according to TNF-α ELISA kit in TNF-α ELISA kit detection supernatant.
5.2.5 data processing
Data processing and mapping use software GraphPad Prism 5.0, statistics average ± standard deviation table
Show, the contrast between group uses one-way analysis of variance (one-way ANOVA), and p < 0.05 are considered significant difference be present between group.
5.3 experimental result
5.3.1 PBMC vigor after separating
Active PBMC, because its cell membrane is intact, trypan blue can not enter cell, show colourless;Dead PBMC,
Trypan blue can enter intracellular, aobvious blue;200 cells are observed, colourless cell there are 192, cell viability 96%, can be used for
Follow-up α-MSH anti-inflammatory activities detection.
5.3.2 NF- κ B p65 protein expressions in PBMC
Using β-actin as reference, NF- κ B p65 expression is analyzed with image J, the results showed that:NF- κ after DSS inductions
B p65 expression raises (the p < 0.01 compared with normal group) significantly;Use the rhodotorula glutinis recombinant bacterial strain for importing α-MSH polypeptides
After culture supernatant processing, NF- κ Bp65 expression effectively declines (pDG7 groups, pDG7+Furin groups the p < 0.05 compared with LPS groups),
The culture supernatant for converting empty carrier is discharged without influence (pDG groups and pDG7+Furin before and after furin enzymolysis on TNF-α
Group contrast, p > 0.05) and using after the Bacteria Culture supernatant processing for secreting α-MSH precursor proteins, this effect suppresses NF- κ
The effect of B p65 expression is more notable (pBDMSH groups, pBDMSH+Furin groups are compared with LPS groups, pDG7 groups, p < 0.01), such as
It is shown in Table shown in 3-1.
Table 3-1 NF- κ B p65 express relative gray values
Table 3-1 Relative gray value of NF-κB p65 expression
Note:aP < 0.01 contrast with N groups,bP < 0.05 contrast with LPS groups,cP < 0.01 are compared with LPS groups, pDG7 groups, n
=5.
5.3.3 recombinant bacterium culture supernatant, which suppresses LPS, stimulates PBMC TNF-α release
PBMC is added after LPS stimulates 8h, and the TNF-α concentration in supernatant largely raises (compared with normal group p<0.01);
The culture supernatant for converting empty carrier is discharged without influence (pDG groups and pDG7+Furin before and after furin enzymolysis on TNF-α
Group compares, p > 0.05);The supernatant liquid energy for converting the bifid bacterium of empty carrier significantly inhibits the generation for the TNF-α that LPS is stimulated, i.e.,
PDG7 groups, pDG7+Furin the groups p compared with LPS groups<0.05;Bacterial supernatant and the conversion for secreting α-MSH precursor proteins are unloaded
Body group, LPS groups are compared to pBDMSH groups compared with LPS groups, pDG7 groups), the secretion (p of TNF-α can be significantly inhibited<0.05);But again
Group bacterium supernatant after furin digests, its suppress TNF-α expression activity greatly improve (pBDMSH+Furin groups and
LPS groups, pDG7 groups, p<0.01) complete α-MSH are obtained after, illustrating enzymolysis and the α-MSH have played its anti-inflammatory activity.
Import effect experiment of the rhodotorula glutinis recombinant bacterial strain of α-MSH polypeptides to experimental colitis
6.1 material
6.1.1 main agents:3.5%DSS solution
6.1.3 experiment mice
46 SPF level BALB/c mouses are bought is in Zhongshan University's Experimental Animal Center, certificate of competency number:SCXK Guangdong
2011--00296.2 method
6.2.1 the structure of animal model
40 mouse are taken, give 3.5%DSS solution as free drinking water, it is continuous to feed 7 days, the excrement of mouse is observed,
Diarrhoea status, TNF-α content in mice serum is detected, modeling is determined, gives up for the unsuccessful mouse of modeling and do not have to.
6.2.2 packet transaction
N groups (normal group), 6 mouse not modeled;DSS groups, the mouse of 8 modelings;
PDG7 groups (empty carrier group), the mouse of 8 modelings is taken, daily except normal feed is fed, also feeding conversion is unloaded
The rhodotorula glutinis recombinant bacterial strain of the importing α-MSH polypeptides of body, every daily scale of feeding is 1 × 1010CFU;PBDMSH groups, take 8
The mouse of modeling, daily except normal feed is fed, also feeding secretion α-MSH restructuring imports the rhodotorula glutinis of α-MSH polypeptides
Recombinant bacterial strain BL-pBDMSH, every daily scale of feeding are 1 × 10 10CFU.The rhodotorula glutinis weight of α-MSH polypeptides is imported in feeding
Group bacterial strain is after seven days, and be euthanized mouse, colon rear end tissue is cut, for detecting the MPO in tissue, TNF-α, IL-1 β, IL-
6th, IL-10 and pathology section examination;α-MSH in knot mucous gut membrane are detected, then are the 1st, 3,5,7 after bifid bacterium is fed
Its detection.
6.2.3 colonic mucus α-MSH are detected
The 1st, 3,5,7 day after bifid bacterium is fed, colonic mucus is collected, 20min is centrifuged under 3000rpm normal temperature, it is heavy to remove
Form sediment, the α-MSH employment α-MSH ELISA kits detection in supernatant, specific method is shown in 2.2.5.
6.2.4 MPO is detected
MPO detection uses Fabia [57] method, and 4.2.5 cytokine TNFs-α, IL-1 β, IL-6 are operated according to kit
With IL-10 measure
Colon 0.1g is weighed, addition PBS to 0.5ml, is fully homogenized, 5000rpm centrifugations 20min at 4 DEG C,
Precipitation is discarded, it is standby to collect supernatant.
A.TNF- α are detected
Using the kit of equation company, operating procedure illustrates B.IL-1 β, IL-6 and IL-10 measure according to kit
Kit of the Bo Ling sections for company is used, step illustrates that 4.2.6 tissue pathological slices are observed according to kit
Colon is taken, is cleaned 3 times with physiological saline, cuts irregular part, clean tissue is placed in containing 10% first
5h is soaked in the solution of aldehyde;Dehydration, transparent, waxdip, embedding, section, dewaxing, dye, seal rear micro- Microscopic observation up for safekeeping and take pictures.
6.2.7 data processing
Data processing and mapping use software GraphPad Prism 5.0, statistics average ± standard deviation table
Show, the contrast between group uses one-way analysis of variance (one-way ANOVA), and the data analysis between two groups uses Student'
S t test, p<0.05 is considered significant difference be present between group.
6.3 result
6.3.1 model construction
Mouse drank the aqueous solution containing 3.5%DSS after seven days, symptom of having loose bowels occurred, excrement scattered paste shape, companion in excrement
With bloodstain, the TNF-α in serum rises to 19.22 ± 1.07pg/ml (p by 9.20 ± 0.41pg/ml<0.05) modeling, is illustrated
Success.
6.3.2 α-MSH are detected
After colitis mice takes bifid bacterium, the 1st, 3,5,7 day after taking, colonic mucus α-MSH concentration is detected.
PBDMSH groups, it will be seen that with the number of days taken, α-MSH amount sustainable growth:At 1-5 days, α-MSH increased sharply,
At 5-7 days, the increased amounts of α-MSH were relatively few, tended to a stable state, its reason be probably at latter several days, colon
The rhodotorula glutinis recombinant bacterial strain arrival peak for importing α-MSH polypeptides is not further added by;Expression quantity compared with pDG7 (empty carrier group) group,
p<0.001.And in pDG7 groups, expression quantity is always maintained at poised state (being shown in Table 4-1 and Figure 11) within degree of detection.
α-MSH concentration (pg/ml) in table 4-1 colon mucus
Table 4-1 Concentration of α-MSH in colon mucinous
Note:* * p < 0.001 and pDG7 is passed through compared with n=5.
6.3.3 MPO activity in colon
After being handled seven days with the rhodotorula glutinis recombinant bacterial strain for importing α-MSH polypeptides, the MPO in tissue is detected with ELISA
Activity, as a result find compared with DSS groups, the MPO of pDG7 groups and pBDMSH groups activity all effectively arrive decline, exist notable
Difference (p < 0.05), but pBDMSH groups are significantly (p < 0.01), are shown in Table 4-2 and Figure 12.
MPO activity in table 4-2 colons
Table 4-2 MPO activity in the colon tissue
Note:* p < 0.05 are compared with DSS groups, and * * p < 0.01 are compared with pDG7, DSS group, n=5.
6.3.4 colon's cytokine TNF-α, IL-1 β, IL-6 and IL-10 expressions
After the long rhodotorula glutinis recombinant bacterial strain for importing α-MSH polypeptides is taken seven days, cell factor IL-1 β, TNF-α, IL-
There is great variety in 6 and IL-10 expression.In pDG7 groups, compared to DSS groups, anticusp inflammation factor TNF-α and IL-6 can have
Effect declines (p < 0.05), and anti-inflammatory cytokines IL-10 substantially rises (p < 0.05).With respect to DSS groups and pDG7 groups, pBDMSH groups
In anticusp inflammation factor TNF-α, IL-1 β, IL-6 are significantly reduced (p < 0.05), and IL-6 is more significantly (p < 0.01), resists
Inflammatory cytokines IL-10 also dramatically increases (p < 0.05), is shown in Table 4-3 and Figure 13.
Cell factor IL-1 β, TNF-α, IL-6 and IL-10 expression in table 4-3 colons
Table 4-3 Expression of cytokines IL-1 β, TNF-α, IL-6 and IL-10 in the
colon tissue
Note:* p < 0.05 are compared with pDG7, DSS group, and * * p < 0.01 are compared with pDG7, DSS group, #p < 0.05 and DSS groups
Compare, n=5.
6.3.5 mouse Colon histotomy is observed
Shown in Figure 14, after hematoxylin-eosin dye dyeing, in normal group (N groups), it may be seen that complete colon
Mucous layer, there is clearly brush border, the arrangement of top layer columnar cell is closely orderly, without any broken sign;In DSS groups,
It can be seen that rotten to the corn mucous membrane, brush border receive damage, it can not be identified and, can't see the columnar cell on top layer, column is thin
Obvious layering is not seen under born of the same parents, shows that serious inflammatory cell invades profit and typical ulcer yet;In empty carrier group (pDG7
Group), it was observed that broken brush border, moreover it is possible to see fuzzy top layer columnar cell, can also see picture between columnar cell's cell
The same white space between cells of bubble;In express alpha-MSH recombinant bacterium group (pBDMSH groups), it can be seen that clearly brush relatively
Edge, surface are serrated, and the columnar cell on top layer also can be also than more visible, but arranges in a jumble, is layered below columnar cell bright
In vain.
Ulcerative colitis (UC), it is really sick although experienced decades of research as a kind of complicated inflammatory bowel disease
Because failing to understand so far.Current treatment method mainly using anti-inflammatory agent glucocorticoid, minosalicylates, drugs and is immunized
Inhibitor etc., can't solve problem at all.In our experiment, we are tested to import the rhodotorula glutinis of α-MSH polypeptides
Anti-inflammatory polypeptide α-MSH are delivered to colon, research carries α-MSH and imports the viscous of α-MSH polypeptides by recombinant bacterial strain as transport vehicle
Antiphlogistic effects of the rhodotorula recombinant bacterial strain to colitis.A series of UC unconventionality expression for primarily showing as inflammatory cytokines,
Body is damaged, therefore suppresses inflammation just as the treatment sick top priority.α-MSH are a kind of human endogenous's nerves
Property polypeptide, it is good to human body affinity, there is very strong antiinflammatory action, the various inflammation medium factors can be adjusted, suitable for this
Disease of the kind with complicated inflammation background, has been reported that confirmation, the polypeptide is expelled in inflammatory bowel disease models Mice Body, Ke Yiqi
To good therapeutic effect, but there is very big problem in this experiment.First, α-MSH half-life period only 20 minutes, injection are only capable of tieing up
The effect of holding in the short time, it is impossible to applied to reality;On the other hand, α-MSH, which have, suppresses pathogenic bacteria such as staphylococcus aureus
With the effect of Candida albicans, cause inflammatory bowel disease for such bacterium, it is harmful thin that injection obviously can not act on α-MSH
Bacterium, therefore be a kind of very reasonless mode, furthermore, α-MSH are polypeptide, orally just also unrealistic.
In order to change this awkward situation, we attempt to import the viscous red ferment of α-MSH polypeptides by oral express alpha-MSH
Female recombinant bacterial strain so form utilizes α-MSH.The rhodotorula glutinis recombinant bacterial strain for importing α-MSH polypeptides is mainly grown in knot
Intestines, the degraded of stomach and enteral protease to α-MSH can be avoided, by the rhodotorula glutinis recombinant bacterium for importing α-MSH polypeptides
Strain, to realize lasting administration, to maintain valid density, reaches therapeutic effect constantly in the secretion α-MSH of colon;Meanwhile can
So that α-MSH directly act on some pathogenic bacteria, this is extremely important to inflammatory bowel disease, because most anti-inflammatory agents only have anti-inflammatory effect
Fruit, the function without suppressing germ.For drug delivery, the rhodotorula glutinis recombinant bacterial strain field planting for importing α-MSH polypeptides exists
Colon, it is also the position of colitis breaking-out herein, is delivered by the rhodotorula glutinis recombinant bacterial strain for importing α-MSH polypeptides, α-MSH are just
Inflammatory tissue can be directly targeted, improves the utilization rate of medicine.The result of mouse colitis model shows, takes express alpha-MSH
Precursor protein bacterial strain, α-MSH precursor proteins can effectively be secreted in colon, be converted in the presence of colon's furin
For α-MSH.5-7 days after taking, α-MSH reached a plateau in the amount of colonic mucus, and valid density it
It is interior, show the effect of a lasting administration.Our data showed that an inflammatory conditions and the mark of tissue damage because
Sub- MPO, after express alpha-MSH bacterial strain is taken, its activity substantially reduces;Anticusp inflammation factor IL-1 β, TNF-α and IL-6 are then
Significantly reduce, also anti-inflammatory cytokines IL-10, be considered to have the albumen of potential treatment inflammatory bowel disease, also significantly increased
Add, illustrate a good anti-inflammatory effect, colon's pathology section examination below has also confirmed our result.We
Experiment change this injection occupation mode of α-MSH polypeptides, realize oral delivery α-MSH, solve asking for its half-life short
Topic.
On the other hand, the treatment of IBD only focuses on that to control inflammation be far from being enough, because this disease is also
Relevant with enteric flora disturbance, rational therapy should be also including regulation gut flora.Studies have reported that some bacteriums are for example big
The pathogenic bacteria such as enterobacteria and avain tuberculosis mycobacteria dramatically increase in inflammatory bowel disease patient's enteron aisle, mycobacteria, monocyte
Increasing property listeria spp, Chlamydia and enterobacteriaceae lactobacteriaceae can cause inflammatory bowel disease.Therefore, control pathogenic bacteria are being treated
Inflammatory bowel disease just seems natural.The rhodotorula glutinis recombinant bacterial strain of α-MSH polypeptides is imported as probiotics, except some health cares
Outside function, moreover it is possible to play barrier action to alimentary canal mucous membrane, suppress the bacteria growing that causes a disease, maintain gut flora balance, also have some to grind
Study carefully the rhodotorula glutinis recombinant bacterial strain for showing to import α-MSH polypeptides to can be used for controlling inflammatory bowel disease, it may be possible to its antibacterial functions have
Close, therefore be applied to inflammatory bowel disease.More there are some researches show the quantity for importing the rhodotorula glutinis recombinant bacterial strain of α-MSH polypeptides is being burst
It is to reduce in the colon of the patient of ulcer colitis, the rhodotorula glutinis recombinant bacterial strain that supplement imports α-MSH polypeptides just seems non-
Often it is necessary.In summary, the rhodotorula glutinis recombinant bacterial strain bacterial strain of oral express alpha-MSH importing α-MSH polypeptides can be used as one
Effective means of the kind with reference to anti-inflammatory and gut flora adjustment for the treatment of inflammatory bowel disease
α-MSH are a kind of human endogenous's nerve polypeptides, and our trials are carrying out mouth with yeast as its carrier
Clothes, by strain construction above, α-MSH is entered intracellular and shown that it is located in oil droplet, passed through this chapter reality
Issue after examination and approval now, after Mouse oral carries α-MSH bacterial strain GM4-D6D- α MSH, α-MSH content is in serum and organs in adult
Middle content significantly increases, and changes α-MSH medication, solves the problems, such as half-life short.It is and real by Tissue distribution
It is more notable to issue after examination and approval content increases of the existing α-MSH in liver, therefore is beneficial to for treating liver diseases.
GLA inherently has the function that antibacterial, anti-inflammatory as polyunsaturated fatty acid, and has many health cares to make
With.We realize GLA overexpression by being overexpressed D6D in rhodotorula glutinis, and unrighted acid is and glycerine mostly
It is stored in reference to rear generation triacylglycerol in oil droplet, then our this experiment is exactly to realize both to be rich in GLA in oil droplet, is contained again
There are α-MSH, by the recombination yeast of oral killed, realize transmission of the yeast for two kinds of anti-inflammatory substances, while red ferment is glued in the strain
Female its fatty acid composition is similar to vegetable oil [10] through this laboratory checking early stage, and containing the carrotene enriched, its into
Dividing has good health-care effect.We have found that after oral whole GM4-D6D- α MSH bacterial strains, not only GLA content increases through experiment
Add, and GLA further product arachidonic acid is that ARA content also increases, and realizes a variety of insatiable hungers in Mice Body
With the increase of content of fatty acid.In summary, the oral whole yeast rich in GLA and α-MSH can simply, effectively realize two
Kind material oral delivery, then this method is also applied for the oral delivery as other polypeptide drugs or dewatering medicament.
After Mouse oral GM4-D6D- α MSH bacterial strains, α-MSH concentration increase in serum and liver, lung, kidney, spleen,
In vital tissue organ, the concentration increase of the α-MSH in liver is more notable;After Mouse oral GM4-D6D- α MSH bacterial strains, blood
GLA, ARA of cleer and peaceful liver concentration increase.
The present invention, as carrier, improves bacterial strain GLA content, and pass through electroporation with rhodotorula glutinis by being overexpressed D6D
Realize that allogenic polypeptide α-MSH and H22LP enter in intracellular oil droplet, and through the oral whole yeast strain GM4-D6D- α of healthy mice
MSH evaluates this method oral delivery α-MSH and GLA effect, and concrete outcome is summarized as follows:
(1) by building foreign gene D6D expression vector pPGK1-rD-D6D, realize Δ 6- delta 8 desaturase genes viscous
Stable heredity in rhodotorula, and D6D overexpression is realized, the GLA contents in recombinant bacterial strain is improved 3.3 compared with wild strain
It is more again.
(2) by electroporation method, realize that allogenic polypeptide enters intracellular, found by laser co-focusing into the more of intracellular
Peptide is located in oil droplet;And the method is applied to two kinds of different polypeptide α-MSH and H22LP, two kinds of polypeptides enter containing for intracellular
Measure no notable difference.
(3) the oral whole bacterial strain GM4-D6D- α MSH for carrying GLA and α-MSH, have found mice serum and vitals
α-MSH content increase in (liver, lung, spleen, kidney), particularly liver improves 3.24 times;GLA's and GLA in serum and liver
Next step product ARA content is also improved, and GLA contents improve about 7.26 times wherein in blood, and arachidonic acid carries
It is high about 1.55 times;GLA contents relatively improve about 4.33 times in liver, and arachidonic acid improves about 1.28 times.
The characteristics of yeast existing unicellular microorganism, such as yeast smaller only several microns, easily culture, cell growth in itself
It is fast etc., also there is feature possessed by eukaryotic, can such as carry out translation after the transcription of eukaryotic, without endotoxin, and
And up to the present yeast studied on science of heredity and structure the characteristics of it is more clear, beneficial to carrying out genetic modification,
Engineering bacteria is built, while yeast can realize industrialization large-scale production, be related to the launch of yeast at present.Yeast serves as
Carrier, the transmission of unrighted acid is realized it has been reported that the unique distinction that we test is can by oral whole yeast
Simultaneously deliver unrighted acid and polypeptide drugs, the special cell wall structure of yeast so that its have to gastral hydrochloric acid in gastric juice compared with
Strong resistant function, good protection can be provided for large biological molecule as a kind of natural biological capsule, protect unsaturated lipid
Fat is not oxidized, protects polypeptide drugs not to be degraded by enzymes.
Above-described embodiment is the preferable embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any Spirit Essences without departing from the present invention with made under principle change, modification, replacement, combine, simplification,
Equivalent replacement mode is should be, is included within protection scope of the present invention.
Claims (8)
1. a kind of rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides, it is characterised in that α-MSH polypeptides are imported and gone through Δ 6-
In the rhodotorula glutinis of saturation enzyme gene restructuring.
A kind of 2. rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 1, it is characterised in that:Δ6-
Desaturase is obtained by the separation of the D6D genes of cunninghamella echinulata with amplification.
A kind of 3. rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 2, it is characterised in that:Δ6-
The rhodotorula glutinis construction method of delta 8 desaturase genes restructuring, the step of it includes, are as follows:
(1) expression vector pPGK1Z-rD-ME extracting;
(2) PGK1 genes and D6D genes are connected;
(3) PGK1-D6D fragments are reacted with the double digestion of expression vector carrier, are connected.
A kind of 4. rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 5, it is characterised in that:It is viscous red
Yeast and the mol ratio of D6D genetic fragments will be controlled 1:3-10.
5. a kind of preparation method of the rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 1, its feature
It is:Including the step of it is as follows:
(1) preparation engineering bacterial strain GM4-D6D bacterial strain competent cells;
(2) totally 100 μ L after mix after the dissolving of α-MSH polypeptides that 10 μ g have been modified with competent cell, are added to electricity and convert cup
In;
(3) electric shockization;
(4) after electric shock terminates, the 1M sorbitol solutions of 900 μ L precoolings are added into conversion cup immediately, is slightly inhaled with rifle and plays mixing,
Then gone in sterilized centrifuge tube, 30 DEG C of standing 1h, the fresh YPD culture mediums of 1mL added after centrifugation thalline is resuspended,
30 DEG C of temperature, 200rpm shake 1 hour;
(5) bacterial strain finally obtained.
6. a kind of preparation method of the rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 5, its feature
It is:The electric shockization step is as follows:
(1) competent cell that oneself prepares by 80 μ L mixes with the 20 μ L DNAs to be transformed linearized, is added to
In the electricity conversion cup of 0.2cm precoolings;
(2) by the electricity conversion cup ice bath 5min equipped with mixed liquor;
(3) parameter of electroporation is adjusted:Voltage 1.5kV, electric capacity 25uF, the Ω of resistance 200, electric shock duration are 5ms;
(4) after electric shock terminates, the 1M sorbitol solutions of 1mL precoolings are added into conversion cup immediately, is slightly inhaled with rifle and plays mixing, so
Gone to afterwards in sterilized centrifuge tube, 30 DEG C of standing 1h, then add the fresh YPD culture mediums of 1mL, 30 DEG C of temperature, turn
Fast 200rpm shakes 1 hour;
(5) 3000rpm at room temperature, 4min is centrifuged, thalline is resuspended with 200 μ L ddH2O;
(6) liquid that will disappear is coated on YPD flat boards, is placed in 30 DEG C of incubators and cultivates 2-3d, untill growing single bacterium colony.
A kind of 7. rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 1, it is characterised in that:For
Treat the application in inflammatory bowel disease medicine and functional food preparation.
A kind of 8. rhodotorula glutinis recombinant bacterial strain of importing α-MSH polypeptides according to claim 1, it is characterised in that:For
Application in the food related to MSH effects or medicine preparation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710289602 | 2017-04-27 | ||
CN2017102896027 | 2017-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107400635A true CN107400635A (en) | 2017-11-28 |
Family
ID=60405051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710370603.4A Pending CN107400635A (en) | 2017-04-27 | 2017-05-23 | Import rhodotorula glutinis recombinant bacterial strain of α MSH polypeptides and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107400635A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110835608A (en) * | 2018-08-15 | 2020-02-25 | 广州溯原生物科技有限公司 | Recombinant rhodotorula glutinis living cell liposome carrying exogenous polypeptide and application thereof |
WO2020082221A1 (en) * | 2018-10-23 | 2020-04-30 | 利时雨 | Live cell liposome of rhodotorula glutinis carrying exogenous polypeptide of recombinant phosphocholine cytidine transferase and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1609224A (en) * | 2004-09-17 | 2005-04-27 | 中国人民解放军第二军医大学 | Recombinant glandular associated virus expression vector carrying alpha-melanophore stimulin gene and its use |
CN101985632A (en) * | 2010-01-19 | 2011-03-16 | 中国农业科学院油料作物研究所 | Application of lipomyces konoenkoae |
WO2011064282A1 (en) * | 2009-11-25 | 2011-06-03 | Novo Nordisk A/S | Method for making polypeptides |
CN104232712A (en) * | 2014-10-21 | 2014-12-24 | 长沙中科晶博生物科技有限公司 | Method for preparing plectasins by saccharomyces cerevisiae |
WO2015117021A1 (en) * | 2014-01-31 | 2015-08-06 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
CN107236679A (en) * | 2017-04-27 | 2017-10-10 | 广州弘宝元生物科技有限公司 | A kind of high yield unrighted acid recombinant strain and its construction method |
-
2017
- 2017-05-23 CN CN201710370603.4A patent/CN107400635A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1609224A (en) * | 2004-09-17 | 2005-04-27 | 中国人民解放军第二军医大学 | Recombinant glandular associated virus expression vector carrying alpha-melanophore stimulin gene and its use |
WO2011064282A1 (en) * | 2009-11-25 | 2011-06-03 | Novo Nordisk A/S | Method for making polypeptides |
CN101985632A (en) * | 2010-01-19 | 2011-03-16 | 中国农业科学院油料作物研究所 | Application of lipomyces konoenkoae |
WO2015117021A1 (en) * | 2014-01-31 | 2015-08-06 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
CN104232712A (en) * | 2014-10-21 | 2014-12-24 | 长沙中科晶博生物科技有限公司 | Method for preparing plectasins by saccharomyces cerevisiae |
CN107236679A (en) * | 2017-04-27 | 2017-10-10 | 广州弘宝元生物科技有限公司 | A kind of high yield unrighted acid recombinant strain and its construction method |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110835608A (en) * | 2018-08-15 | 2020-02-25 | 广州溯原生物科技有限公司 | Recombinant rhodotorula glutinis living cell liposome carrying exogenous polypeptide and application thereof |
WO2020082221A1 (en) * | 2018-10-23 | 2020-04-30 | 利时雨 | Live cell liposome of rhodotorula glutinis carrying exogenous polypeptide of recombinant phosphocholine cytidine transferase and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102512458A (en) | Semi-bionic extraction method for active components of Cordyceps militaris | |
Wu et al. | Mycelial fermentation characteristics and anti-fatigue activities of a Chinese caterpillar fungus, Ophiocordyceps sinensis strain Cs-HK1 (Ascomycetes) | |
CN109481476A (en) | Application of the lactobacillus fermenti CQPC04 in the food or drug that preparation improves ulcerative colitis | |
TW201200143A (en) | A method to improve cordycepin of Solid-state cultivation | |
CN114099556A (en) | Yeast powder rich in nicotinamide mononucleotide, preparation method and application thereof | |
CN109897788A (en) | A kind of rape rod method and preparing the application in bacteriostatic agent | |
CN107400635A (en) | Import rhodotorula glutinis recombinant bacterial strain of α MSH polypeptides and its preparation method and application | |
TW201625282A (en) | Novel Acetobacter and Gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | |
CN113430148A (en) | Fermentation medium of animal bifidobacterium and application thereof | |
JP2024019630A (en) | New microalgae | |
CN106047956B (en) | A method of the Penicillium citrinum Asc2-4 that grown nonparasitically upon another plant altogether using ascidian fermentation preparation is rich in the grease of gamma-Linolenic acid | |
CN107345211A (en) | Introduce living cells liposome and its application of allogenic polypeptide | |
CN107236679A (en) | A kind of high yield unrighted acid recombinant strain and its construction method | |
CN114854604B (en) | Ganoderma lucidum, high-concentration oral liquid containing ganoderma lucidum and preparation method thereof | |
CN103275901A (en) | Space-induced efficient bacillus natto, application of bacillus natto and preparation method of troche of bacillus natto | |
CN113774000B (en) | Bifidobacterium animalis fermentation filtrate, preparation method and application thereof | |
CN105441344B (en) | One plant of candida utili and its application with anti-oxidation function | |
CN104593307A (en) | Lactobacillus rhamnosus with angiotensinase inhibiting function and application of lactobacillus rhamnosus | |
CN104130949B (en) | A kind of the liquid deep layer fermenting culture medium and cultural method of rich iron Cordyceps militaris | |
CN104651272B (en) | Lactobacillus casei Lactobacillus casei strain Qian working stock cultures products and its enteron aisle adjust dietetic use | |
CN112933116B (en) | Application of lactobacillus plantarum in preparation of vascular protecting agent | |
CN106010988B (en) | One plant of ascidian grows nonparasitically upon another plant Penicillium citrinum Asc2-4 altogether | |
CN106544243B (en) | Preparation method of cordyceps sobolifera wine | |
CN115093972B (en) | Cordyceps militaris strain and application thereof | |
TWI791918B (en) | Use of mycelium of deinococcus spp. for manufacturing pharmaceutical composition for angiogenesis inhibition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171128 |